US EditionTransitioning Patients From IVIg to SCIg in CIDP
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
City of Selkirk Proclamation - GBS and CIDP Awareness Month
WHEREAS: the Month of May, has been internationally designated as “GBS and CIDP Awareness Month” to educate the public and to focus attention on Guillain-Barré Syndrome (GBS) and Chronic Inflammatory… The post City of Selkirk Proclamation – GBS and CIDP Awareness Month appeared first on City of Selkirk.
Transitioning Patients From IVIg to SCIg in CIDP
Panelists discuss how transitioning stable patients with chronic inflammatory demyelinating polyneuropathy (CIDP) from intravenous immunoglobulin (IVIg) to subcutaneous immunoglobulin (SCIg) can offer greater convenience and independence, with careful consideration of dosing, patient education, and ongoing monitoring to ensure successful treatment outcomes.
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
